Pharmacogenomics In Psychiatry

Psychiatric Pharmacogenomics is a book written to help clinicians to use pharmacogenomic testing to improve the pharmacotherapy that they provide for their patients. It is designed to teach clinicians how to order pharmacogenomic tests and interpret the results. Clinical examples are used to underscore the specific indications for pharmacogenomic testing and to clarify the clinical usefulness of identifying atypical genotypes that result in problematic responses to medication. The first section of the book begins with a basic review of molecular genetics. Additionally, the book also includes an extensive glossary of technical terms associated with molecular genetics and pharmacogenomics. The clinical utility of pharmacogenomic testing is demonstrated throughout the book by describing the implications of genetic variations for the care of individual patients. The second section of the book is organized into fourteen chapters that each focus on the clinical implications of testing for specific genes for which variants have been associated with either therapeutic response or side effects of psychotropic medications. Each of these chapters is structured in the same manner and involves a description of the gene and its significant variants. Each chapter also includes one or more clinical vignettes. The third section of the book discusses the clinical usefulness of pharmacogenomic testing, ethical issues associated with pharmacogenomic testing, and provides predictions for the future development of more sophisticated pharmacogenomic testing.

In recent years, there have been major developments in the fields of pharmacogenetics and pharmacogenomics, with the potential to make drug treatments in psychiatric medicine more effective. However, improvements in drug efficacy and tolerability, as well as finding the optimal dosage, can only be realized if in vivo mechanisms of drug action and ADME (absorption, distribution, metabolism, excretion) processes (pharmacokinetics) of psychopharmacological agents are better understood. In this volume, current progress and perspectives in pharmacogenetic testing of drug-metabolizing enzymes, drug transporters and other drug targets involved in the response to psychotropic agents are described extensively. This provides a timely overview of what has been achieved in the area of psychiatric pharmacogenomics alongside some promising directions and perspectives for future research.Psychiatrists, general medical doctors as well as pharmacologists and clinical pharmacologists will find new insights into the development and applications of pharmacogenomics in psychiatry.

Psychiatric Pharmacogenomics is a book written to help clinicians to use pharmacogenomic testing to improve the pharmacotherapy that they provide for their patients. It is designed to teach clinicians how to order pharmacogenomic tests and interpret the results. Clinical examples are used to underscore the specific indications for pharmacogenomic testing and to clarify the clinical usefulness of identifying atypical genotypes that result in problematic responses to medication. The first section of the book begins with a basic review of molecular genetics. Additionally, the book also includes an extensive glossary of technical terms associated with molecular genetics and pharmacogenomics. The clinical utility of pharmacogenomic testing is demonstrated throughout the book by describing the implications of genetic variations for the care of individual patients. The second section of the book is organized into fourteen chapters that each focus on the clinical implications of testing for specific genes for which variants have been associated with either therapeutic response or side effects of psychotropic medications. Each of these chapters is structured in the same manner and involves a description of the gene and its significant variants. Each chapter also includes one or more clinical vignettes. The third section of the book discusses the clinical usefulness of pharmacogenomic testing, ethical issues associated with pharmacogenomic testing, and provides predictions for the future development of more sophisticated pharmacogenomic testing.

Psychiatric Genomics presents and synthesizes available knowledge in the field of psychiatric genomics, offering methodologies to advance new research and aid clinical translation. After providing an introduction to genomics and psychiatry, international experts discuss the genomic basis of schizophrenia, bipolar disorder, depression, personality disorders, anxiety disorders, addictions, eating disorders, and sleep disorders, among other disorders. In addition, recommendations for next steps in clinical implementation and drug discovery are discussed in-depth, with chapters dedicated to pharmacogenomics and antipsychotics, antidepressants and mood stabilizers, adverse drug reactions, implementation of pharmacogenomics in psychiatric clinics, and ethical issues. Finally, methods sections provide a solid grounding in research approaches and computational analytics, from using animal models in psychiatric genomics and accessing biobanks, to employing computational analysis, genome-wide association studies (GWAS), brain pathophysiology, and endophenotypes in psychiatric research. Thoroughly examines the genetic mechanisms underlying a broad range of psychiatric disorders Offers genomic methodologies and analytical approaches supporting new research and clinical translation, including personalized diagnosis and treatment models Features chapter contributions from international leaders in the field

This book provides an introduction to the principles of pharmacogenomics and precision medicine, followed by the pharmacogenomics aspects of major therapeutic areas such as cardiovascular disease, cancer, organ transplantation, psychiatry, infection, antithrombotic drugs. It also includes genotyping technology and therapeutic drug monitoring in Pharmacogenomics; ethical, Legal and Regulatory Issues; cost-effectiveness of pharmacogenetics-guided treatment; application of pharmacogenomics in drug discovery and development and clinical Implementation of Pharmacogenomics for Personalized Precision Medicine. The contributors of Pharmacogenomics in Precision Medicine come from a team of experts, including professors from academic institutions and practitioner from hospital. It will give an in-depth overview of the current state of pharmacogenomics in drug therapy for all health care professionals and graduate students in the era of precision medicine.

Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation includes discussions and viewpoints from the academic, regulatory, pharmaceutical, clinical, socio-ethical and economic perspectives. Each chapter presents an overview of the potential or opportunity within the areas discussed and also outlines foreseeable challenges and limitations in moving pharmacogenomics into drug development and direct therapeutic applications. This edited book contains review questions for a more in-depth analysis of the implications of pharmacogenomics and discussion points to generate ideas on best to move the field forward. Clinical pearls and case studies are used to illustrate real-life experiences and both successful and unsuccessful applications. Tables, figures, and annotations are included throughout the book to facilitate understanding and further reference. Multi-contributed book and chapters are written by contributors who are experts in their field Provides perspectives from those involved in all aspects of pharmacogenomics—including academic, regulatory, economic, industry and medical—to illustrate how all of the pieces fit together and where the challenges may be Includes case studies of both successful and unsuccessful applications so readers can consider the potential and challenges in moving the science into drug development and direct therapeutic applications Chapters contain discussion questions and clinical pearls and enable readers to reflect on how to move pharmacogenomics forward and apply these observations and useful tips to their own work and research

In recent years, there have been major developments in the fields of pharmacogenetics and pharmacogenomics, with the potential to make drug treatments in psychiatric medicine more effective. However, improvements in drug efficacy and tolerability, as well as finding the optimal dosage, can only be realized if in vivo mechanisms of drug action and ADME (absorption, distribution, metabolism, excretion) processes (pharmacokinetics) of psychopharmacological agents are better understood. In this volume, current progress and perspectives in pharmacogenetic testing of drug-metabolizing enzymes, drug transporters and other drug targets involved in the response to psychotropic agents are described extensively. This provides a timely overview of what has been achieved in the area of psychiatric pharmacogenomics alongside some promising directions and perspectives for future research. Psychiatrists, general medical doctors as well as pharmacologists and clinical pharmacologists will find new insights into the development and applications of pharmacogenomics in psychiatry.

Personalized Psychiatry presents the first book to explore this novel field of biological psychiatry that covers both basic science research and its translational applications. The book conceptualizes personalized psychiatry and provides state-of-the-art knowledge on biological and neuroscience methodologies, all while integrating clinical phenomenology relevant to personalized psychiatry and discussing important principles and potential models. It is essential reading for advanced students and neuroscience and psychiatry researchers who are investigating the prevention and treatment of mental disorders. Combines neurobiology with basic science methodologies in genomics, epigenomics and transcriptomics Demonstrates how the statistical modeling of interacting biological and clinical information could transform the future of psychiatry Addresses fundamental questions and requirements for personalized psychiatry from a basic research and translational perspective